Company Response Genetics, Inc. Nasdaq
Equities
US76123U1051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2016 | Response Genetics, Inc Bankruptcy Case Dismissed | CI |
2016 | Motion for Case Dismissal Filed for Response Genetics, Inc | CI |
Business Summary
Sales per Business
USD in Million | 2013 | Weight | 2014 | Weight | Delta |
---|---|---|---|---|---|
Pharmacogenomic Tests
100.0
%
| 20 | 100.0 % | 17 | 100.0 % | -15.56% |
Sales per region
USD in Million | 2013 | Weight | 2014 | Weight | Delta |
---|---|---|---|---|---|
United States
91.7
%
| 15 | 76.8 % | 15 | 91.7 % | +0.77% |
Europe
7.9
%
| 4 | 18.0 % | 1 | 7.9 % | -62.81% |
Other International
0.4
%
| - | - | 0 | 0.4 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kevin Roy Harris
DFI | Director of Finance/CFO | 55 | 20/12/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Roy Harris
DFI | Director of Finance/CFO | 55 | 20/12/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,795,396 | 38,795,396 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Response Genetics, Inc.
1640 Marengo Street 7th floor
90033, Los Angeles
+
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.4B | |
+46.00% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- RGDXQ Stock
- Stock
- Company Response Genetics, Inc.